Reducing the neglected burden of viral hepatitis in Africa: Strategies for a global approach

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 469-476

  Lemoine, Maud ^a   Eholié, Serge ^b,c   Lacombe, Karine ^d,e  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University Hospital of Treichville   (Côte d’Ivoire)

^c UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^d HÔPITAL SAINT ANTOINE   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Africa; Hepatitis B; Hepatitis C; Screening; Treatment

Indexed keywords

ANTIVIRUS AGENT;

AFRICA; CHRONIC LIVER DISEASE; DISEASE SURVEILLANCE; DRUG COST; FOLLOW UP; GOVERNMENT; HEALTH; HUMAN; LIVER DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCREENING; VIRUS HEPATITIS; COST OF ILLNESS; ECONOMICS; HEPATITIS, VIRAL, HUMAN; MORBIDITY; NEGLECTED DISEASE; PRACTICE GUIDELINE; TRENDS;

AFRICA; COST OF ILLNESS; HEPATITIS, VIRAL, HUMAN; HUMANS; MORBIDITY; NEGLECTED DISEASES; PRACTICE GUIDELINES AS TOPIC;

EID: 84922241086     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.10.008     Document Type: Review

References (72)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342.
3. Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, et al. Cancer burden in Africa and opportunities for prevention. Cancer 2012; 118(18): 4372-4384.
4. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol 2013; 58: 593-608.
5. ELPA. Report on hepatitis patient self-help in Europe. European Liver Patients Association http://wwwhepbcppaorg/wp-content/uploads/2011/11/Report-on-Patient-Self-Helppdf 2010. Last accessed 3rd of June 2014. 2010.
6. IoM. Hepatitis and liver cancer: A national strategy for prevention and control of hepatitis B and C. The National Academies Press; 2010.
7. WHO. http://apps.who.int/gb/ebwha/pdf-files/WHA63/A63-15-en.pdf. Last accessed 18 June 2014.
8. WHO. http://www.who.int/csr/disease/hepatitis/GHP-framework.pdf. Last accessed 8 May 2014. 2012.
9. Wiersma ST, McMahon B, Pawlotsky J-M, Thio CL, Thursz M, Lim SG, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: Expert panel consensus. Liver Int 2010; 31: 755-761.
10. Organization WH. Guidelines for the screening, care and treatment of persons infected with hepatitis C. http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755-eng.pdf?ua=1& ua=1 2014.
11. Group TLE. Only just the beginning of the end of hepatitis C. The Lancet 2014; 383.
12. Thomas DL. Global control of hepatitis C: Where challenge meets opportunity. Nat Med 2013; 19: 850-858.
13. Thursz M, Njie R, Lemoine M. Hepatitis: Global eradication of hepatitis Bfeasible or fallacy? Nat Rev Gastroenterol Hepatol 2012; 9: 492-494.
14. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, et al. The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004; 39: 211-219.
15. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H, et al. Part I: Cancer in Indigenous Africans-burden, distribution, and trends. Lancet Oncol 2008; 9: 683-692.
16. Hainaut P, Boyle P. Curbing the liver cancer epidemic in Africa. Lancet 2008; 371: 367-368.
17. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
18. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377: 1198-1209.
19. Lessells RJ, Cooke GS. Effect of the HIV epidemic on liver cancer in Africa. Lancet 2008; 371: 1504.
20. Cooper CL, Mills E, Wabwire BO, Ford N, Olupot-Olupot P. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub- Saharan Africa. Int J Infect Dis 2009; 13: 302-306.
21. Cooke G, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A, et al. Viral hepatitis and the Global Burden of Disease: A need to regroup. J Viral Hepatogastroenterol 2013; 20: 600-601.
22. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219.
23. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13: S47-S49.
24. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002; 2: 293-302.
25. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: Results from a nationwide survey. J Viral Hepat 2012; 19: 560-567.
26. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011; 378: 571-583.
27. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub- Saharan Africa: An association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010; 14: E1024-e1031.
28. Lemoine M, Thursz M. Hepatitis C a global issue: Access to care and new therapeutic and preventive approaches in resource-constrained areas. Semin Liver Dis 2014; 34: 89-97.
29. Alliance. WH. Available at: Http://www.who.int/immunization/topics/hepatitis-b-survey-2010/en/. Last accessed 7 May 2014. 2010.
30. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013; 310: 974-976.
31. Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program. BMC Infect Dis 2014; 14: 7.
32. World Health Organization Department of Immunization V. http://www.who.int/immunization/monitoring-surveillance/Global-Immunization-Data.pdf?ua=1. Last accessed 24 June 2014.
33. GAVI. http://www.gavialliance.org/support/nvs/hepb/. 2010.
34. Howell J, Lemoine M, Thursz M. Prevention of materno-foetal transmission of hepatitis B in sub-Saharan Africa: The evidence, current practice and future challenges. J Viral Hepat 2014; 21(6): 381-396.
35. Candotti D, Danso K, Allain JP. Maternofetal transmission of hepatitis B virus genotype E in Ghana, West Africa. J Gen Virol 2007; 88: 2686-2695.
36. Hauri A, Hutin Y, Armstrong G. Contaminated injections in health care settings. In: Ezzati M, Mopez A, Rodgers A, Murray C, editors. Comparative quantification of health risks, 2. Geneva: WHO; 2004. p. 1803-1850.
37. Pepin J, Labbe AC, Mamadou-Yaya F, Mbelesso P, Mbadingai S, Deslandes S, et al. Iatrogenic transmission of human T cell lymphotropic virus type 1 and hepatitis C virus through parenteral treatment and chemoprophylaxis of sleeping sickness in colonial Equatorial Africa. Clin Infect Dis 2010; 51: 777-784.
38. Njouom R, Caron M, Besson G, Ndong-Atome GR, Makuwa M, Pouillot R, et al. Phylogeography, risk factors and genetic history of hepatitis C virus in Gabon, central Africa. PLoS One 2012; 7: E42002.
39. Kandeel AM, Talaat M, Afifi SA, El-Sayed NM, Abdel Fadeel MA, Hajjeh RA, et al. Case control study to identify risk factors for acute hepatitis C virus infection in Egypt. BMC Infect Dis 2012; 12: 294.
40. Paez Jimenez A, Sharaf Eldin N, Rimlinger F, El-Daly M, El-Hariri H, El- Hoseiny M, et al. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 2010; 59: 1554-1560.
41. Raguin G, Lepretre A, Ba I, Ndoye I, Toufik A, Brucker G, et al. Drug use and HIV in West Africa: A neglected epidemic. Trop Med Int Health 2011; 16: 1131-1133.
42. Bowring AL, Luhmann N, Pont S, Debaulieu C, Derozier S, Asouab F, et al. An urgent need to scale-up injecting drug harm reduction services in Tanzania: Prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011. Int J Drug Policy 2013; 24: 78-81.
43. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21: 60-89.
44. Lemoine M, Shimakawa Y, Goldin R, Khalil M, Lloyd J, Suso P, Nayagam S, et al. Validation and comparison of non-invasive markers of liver fibrosis in West-African patients with chronic hepatitis B living in The Gambia, West Africa. EASL, April 9-13, London, UK. 2014.
45. Bonnard P, Sombie R, Lescure FX, Bougouma A, Guiard-Schmid JB, Poynard T, et al. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg 2010; 82: 454-458.
46. Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, et al. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: The case of Egypt. Clin Infect Dis 2014; 58: 1064-1071.
47. WHO. Guidelines for the screening, care and treatment of persons infected with hepatitis C. http://appswhoint/iris/bitstream/10665/111747/1/9789241548755-engpdf?ua=1& ua=1. Last accessed 18/06/2014. 2014.
48. UNITAID. http://www.unitaid.org/en/resources/press-centre/releases/1352- unitaid-approves-grants-of-160-million. Last accessed 18/06/2014. 2014.
49. Thomas DL. Curing hepatitis C with pills: A step toward global control. Lancet 2010; 376: 1441-1442.
50. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007; 45: 579-587.
51. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
52. Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide cohort study. Gastroenterology 2014; 147(1): 143-151.
53. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2012; 381(9865): 468-475.
54. http://www.stridesarco.com/pdf/pressrelease/2013/Strides-Arcolab-Product-Approval-PR-August-1-2013.pdf. Last accessed 24 June 2014.
55. Delfraissy J-F. http://www.lemonde.fr/sciences/article/2014/03/17/inegalites- face-a-l-hepatite-c-4384588-1650684.html. 2014.
56. Callaway E. Hepatitis C drugs not reaching poor. Nature 2014; 508: 295-296.
57. Njai HF, Shimakawa Y, Ferguson L, Sanneh B, Dalessandro U, Njie N, et al. Performance of two rapid tests of hepatitis B surface antigen for screening hepatitis B virus (HBV) infection in the rural communities of The Gambia. J Hepatol 2014; 60: S522.
58. Bottero J, Boyd A, Gozlan J, Lemoine M, Carrat F, Collignon A, et al. Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. J Hepatol 2013; 58: 473-478.
59. Visseaux B, Larrouy L, Calin R, Katlama C, Poynard T, Ratziu V, et al. Virus antibody detection in oral fluid: Influence of human immunodeficiency virus co-infection. J Clin Virol 2013; 58: 385-390.
60. Jardi R, Rodriguez-Frias F, Buti M, Schaper M, Valdes A, Martinez M, et al. Usefulness of dried blood samples for quantification and molecular characterization of HBV-DNA. Hepatology 2004; 40: 133-139.
61. Mohamed S, Raimondo A, Penaranda G, Camus C, Ouzan D, Ravet S, et al. Dried blood spot sampling for hepatitis B virus serology and molecular testing. PLoS One 2013; 8: E61077.
62. Tuaillon E, Mondain AM, Meroueh F, Ottomani L, Picot MC, Nagot N, et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology 2010; 51: 752-758.
63. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, et al. Clinical utility of total HCV core antigen quantification: A new indirect marker of HCV replication. Hepatology 2002; 36: 211-218.
64. Chevaliez S, Soulier A, Poiteau L, JM. P. Clinical Utility of HCV Core antigen quantification in patients with chronic hepatitis C Hepatology; 2013; Suppl. 1: 913.
65. Tagny CT, Mbanya D, Murphy EL, Lefrere JJ, Laperche S. Screening for hepatitis C virus infection in a high prevalence country by an antigen/antibody combination assay versus a rapid test. J Virol Methods 2014; 199: 119-123.
66. WTO. Agreement on trade-related aspects of intellectual property rights. http://www.wto.org/english/docs-e/legal-e/27-trips.pdf. Last accessed 3rd June 2014. 1994.
67. http://www.who.int/medicines/areas/policy/tripshealth.pdf?ua=1. Last accessed 24 June 2014.
68. Monde MD. http://www.hepcoalition.org/IMG/pdf/201406-mdm-policyvhc- en-web.pdf. Last accessed 21 June 2014.
69. Lemoine M, Girard PM, Thursz M, Raguin G. In the shadow of HIV/AIDS: Forgotten diseases in sub-Saharan Africa. Global health issues and funding agency responsibilities. J Public Health Policy 2012; 33(4): 430-438.
70. Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in sub- Saharan Africa. Lancet 2002; 359: 1851-1856.
71. UNAIDS.http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. Last accessed 3rd of June 2014. 2013.
72. World Health Organization, Global Hepatitis Programme, Global partners. http://liver.stanford.edu/files/calltoaction.pdf. Last accessed 3rd June 2014. 2014.